AC Immune (NASDAQ:ACIU) Upgraded to “Strong-Buy” at Zacks Research

by · The Markets Daily

AC Immune (NASDAQ:ACIU – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

A number of other equities analysts have also weighed in on ACIU. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

View Our Latest Stock Report on ACIU

AC Immune Stock Up 0.8%

ACIU opened at $2.62 on Tuesday. The firm has a market capitalization of $266.64 million, a P/E ratio of -4.85 and a beta of 1.60. AC Immune has a one year low of $2.10 and a one year high of $4.00. The company has a fifty day moving average price of $2.59 and a 200-day moving average price of $2.67. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.93 and a quick ratio of 1.02.

AC Immune (NASDAQ:ACIU – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. Equities research analysts expect that AC Immune will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Large investors have recently added to or reduced their stakes in the business. AXQ Capital LP purchased a new position in AC Immune in the 2nd quarter worth $25,000. Dimensional Fund Advisors LP boosted its position in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after buying an additional 176,701 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after buying an additional 30,035 shares during the period. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

(Get Free Report)

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.

See Also